The shares of European firms outside of Britain would suffer more in the event of a poorly executed Brexit, a strategist told CNBC Tuesday. Speaking to CNBC’s “Squawk Box Europe,” Ralph Jainz, a fund manager at Centricus Asset Management, said a negative Brexit outcome had “for sure” been underpriced by investors.READ MORE...

American consumers were feeling less confident this month amid continued volatility in the financial markets. The Conference Board, a business research group, says its consumer confidence index fell to 124.1 in March from 131.4 in February.READ MORE...

European lawmakers have approved sweeping copyright reforms that could have far-reaching consequences for the business models of tech giants like Google and Facebook. The law is aimed at bringing the EU’s rules on copyright into the 21st century to help artists and publishers whose works have been widely dispersed on the internet.READ MORE...

This is the first ever credit card to be offered by Goldman Sachs. According to a memo obtained by CNBC, David Solomon, CEO at Goldman Sachs said, “This partnership is a major step in the growth of our consumer franchise, furthering our vision to create the leading digital consumer platform.” Customers will be eligible for cashbacks, including 2% cashback on all Apple Pay purchases made with the card and 3% upon buying at the Apple Stores or at the App Store.These cashbacks would be added to the users Apple Cash card daily and could be put to use instantly. 

The U.S. Federal Trade Commission is seeking additional information from Bristol-Myers Squibb Co and Celgene Corp.The focus of their investigation is on the companies’ psoriasis treatments as part of its review of their planned merger, Bristol-Myers said. “The parties understand that the FTC’s review is focused on marketed and pipeline products for the treatment of psoriasis,” Bristol-Myers said in a filing. Celgene’s psoriasis drug Otezla brought $448 million in sales in the quarter ended Dec. 31. 

U.S.President Donald Trump’s administration has stepped up its attack on the Obamacare healthcare law, telling a federal appeals court it agrees with a Texas judge’s ruling that the entire law is unconstitutional and should be struck down.  Read more...

Cronos Group's stock  traded lower on Tuesday, after the company reported its latest results. The cannabis company reported revenue of C$5.6 million ($4.2 million) for the fourth quarter, up from $1.6 million a year ago. Its gross profit before fair value adjustments came in at C$2.5 million for the quarter. For the full year, Cronos had a loss of -11 cents per share, compared to a profit of 1 cent a year earlier.Its full-year revenue of $15.7 million was higher than the previous year’s $4.1 million. Mike Gorenstein, CEO of Cronos Group highlighted the company’s expanding presence in domestic and international markets, and its launch of iconic brands for the Canadian adult-use market.

Apple Inc. unveiled plans for four new businesses, sending its stock price higher on Tuesday. At the "It's Showtime" event on the company's Cupertino, California campus, the iPhone maker gave a glimpse into the four new territories that it is heading into – news (Apple News), video/TV streaming (Apple TV+), mobile video gaming (Apple Arcade) and credit cards (Apple Card).Some analysts are predicting that the newly announced businesses could catapult Apple’s overall services revenue to around $60 billion next year. Some analysts’ are contemplating that Apple Pay could potentially turn out to be the most profitable out of the four new service segments.  

The news led to the home goods retailer ‘s shares soaring +25% Tuesday. Citing anonymous people familiar with the matter, CNBC reported that Legion Partners Asset Management, Macellum Advisors and Ancora Advisors are joining forces to use their combined 5% stake in Bed, Bath & Beyond to launch a proxy fight at the retail giant.They would rather consider sales of underperforming assets such as Buy Buy Baby and decor retail chain Cost Plus World Market (according to the CNBC report citing another person familiar with the matter). Analysts have been expecting Bed Bath & Beyond's revenue to decline -10.2% to $3.3 billion when it reports quarterly results on April 10.

The combined entity will retain the Cousins name. The real estate investment trusts will engage in a $1.5 billion all-stock deal, wherein Cousins will issue 2.98 new common shares in exchange for each share of Tier REIT stock.The synergy is expected to bring in $18.5 million of annual net savings. If the deal gets finalized, Cousins shareholders will hold the majority stake – around 72% - in the combined company, and Tier shareholders will own the rest.

Rent-A-Center (Nasdaq: RCII) rents household durable goods to customers and seems like more of a retail-oriented company, but it is actually classified as an industrial company.Regardless of the industry classification, the stock has been performing very well over the last three months. We see on the daily chart that the volatility on Rent-A-Center increased dramatically at the end of December and initially fell sharply.

Application software company Atlassian (Nasdaq: TEAM) has some of the best fundamental indicators of all stocks right now.I am using Investor’s Business Daily’s EPS rating, SMR rating, and Composite Rating as a reference point and we will get to those fundamental ratings later.

Electronics manufacturer Jabil (NYSE: JBL) had an incredible run in January and February, jumping the $23 area all the way up to $29.50.Previous predictions on Jabil have been accurate 66% of the time. Looking at the daily chart we see that the pullback was halted just above the 50-day moving average and the stock has been hovering just above the ascending trend line for several days now.

Since the December low when the stock was under $120, it had bounced back up to above $165 before pulling back in the last few weeks . Despite the roller coaster ride, it looks like the stock has found support at the $150 level and is hovering just above it currently.They have climbed slightly and are just above oversold territory at this time and the indicators just made a bullish crossover. The Tickeron AI Trend Prediction tool generated a bullish signal on Autodesk on March 18.

The 50-day moving average was just below that level and still climbing. The daily stochastic readings for Dana dropped sharply during the two-week pullback, moving from overbought territory to oversold territory.Now the indicators have turned higher and have made a bullish crossover. The Tickeron AI Trend Prediction tool generated a bullish signal on March 15 and that signal called for a gain of at least 2% for the coming week.

Dealing a fresh blow to Boeing, who has been grappling with the grounding of its best-selling jet 737 Max, its arch and biggest rival Airbus announced on Monday that the company has secured a $35 billion jet deal from China. Signed during the recent French capital visit of the Chinese President Xi Jinping, according to the terms of the deal, Toulouse-based Airbus is likely to supply 300 passenger jets to Chinese airlines. In an official statement, Airbus has confirmed that it had signed an agreement with China Aviation Supplies Holding Company, covering the purchase by Chinese airlines of Airbus aircraft including 290 A320-series narrow-body planes and 10 A350 XWB wide-body jet. Airbus’s Commercial Aircraft President, Guillaume Faury, said in a statement that the company "is honored to support the growth of China's civil aviation with our leading aircraft families - single-aisle and wide-bodies." The mammoth order for Airbus is likely to be a big blow for Boeing, as it contrasts st

With subscription services emerging as the new mantra across different industries to lure customers, Restaurant Brands International’s Burger King on Thursday announced the launch of its $5 monthly coffee subscription plan to build brand loyalty. According to the company, the coffee subscription program would be run through its app and is likely to get customers into their stores in the morning to check out their other breakfast offerings. With the battle between the fast food restaurants like Burger King, McDonald’s and Dunkin’ heating up in recent times for a greater share of the early morning customers, Burger King seems to win the first round with its innovative coffee subscription program. Furthermore, the company also introduced its own brand of coffee following the footsteps of its arch rival McDonald’s, who had recently launched McCafe.The company has also been investing in digital across all of its portfolio.

Gaming software company Take-Two Interactive Software (Nasdaq: TTWO) has been trending lower over the last six months and it hasn’t bounced back as much as other stocks.There are two hurdles the stock faces at this point—the upper rail of a downward sloped channel and the 50-day moving average.

Gunning for its biggest deal in nearly two decades, McDonald’s on Monday announced its plan to acquire Israeli personalization and decision logic technology company, Dynamic Yield. The acquisition is in line with the company’s recent push towards technology across its different U.S. locations, as the company tries to come to terms with the digital revolution. According to the company, McDonald’s is one of the pioneers within its industry space to integrate decision technology into the customer point of sale at a brick and mortar location.The acquisition is likely to help the company by changing digital drive-thru menus based on different factors like weather conditions and the current restaurant traffic. Although the financial details of the deal are yet to be confirmed by either company, according to sources close to the deal McDonald’s is likely to pay more than $300 million - its biggest acquisition in two decades. In 2019, according to the company, it is likely s

AstraZeneca plc says the European Commission (EC) has approved a label expansion of its diabetes drug, Forxiga. Forxiga can now be used along with insulin in patients with Type-1 diabetes and a Body Mass Index (BMI) of 27 or more when insulin alone has not been able to control blood sugar levels, the company said.  Farxiga or Forxiga, as the drug is known outside the United States, is one of AstraZeneca’s top ten drugs by sales.It generated $1.39 billion in 2018.